<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3308">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524234</url>
  </required_header>
  <id_info>
    <org_study_id>CARDY CRIT COVID</org_study_id>
    <nct_id>NCT04524234</nct_id>
  </id_info>
  <brief_title>Cardiac Dysfunction in Critically Ill Patients With COVID-19</brief_title>
  <acronym>CARDYCOVID</acronym>
  <official_title>Cardiac Dysfunction in Critically Ill Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The&#xD;
      aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically&#xD;
      ill patients infected with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The&#xD;
      aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically&#xD;
      ill patients with COVID-19. Patients admitted to the intensive care unit, with COVID-19 are&#xD;
      examined with echocardiography for assessment of left and right ventricular dysfunction&#xD;
      within 72 hours from admission and repeated after four to seven days.&#xD;
&#xD;
      Cardiac dysfunction was defined as having either left ventricular (LV) dysfunction, defined&#xD;
      as having an ejection fraction &lt;50% and/or regional hypokinesia, or right ventricular (RV)&#xD;
      dysfunction, defined as having a tricuspid annular plane excursion (TAPSE) &lt;17mm or a&#xD;
      moderate/severe RV dysfunction assessed visually.&#xD;
&#xD;
      The cardiac biomarkers troponin and NTproBNP and clinical data are recorded at time of each&#xD;
      echo. Mortality status is recorded at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All cause death in patients with vs without cardiac dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular dysfunction</measure>
    <time_frame>Within 72 hours from admission</time_frame>
    <description>Prevalence of left ventricular dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular dysfunction</measure>
    <time_frame>Within 72 hours from admission</time_frame>
    <description>Prevalence of right ventricular dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk-factors</measure>
    <time_frame>Within 72 hours from admission</time_frame>
    <description>Clinical variables associated with risk of having cardiac dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac biomarkers</measure>
    <time_frame>Within 72 hours from admission</time_frame>
    <description>Levels of cardiac biomarkers in patients with vs without cardiac dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular dysfunction</measure>
    <time_frame>During ICU-stay</time_frame>
    <description>Prevalence of left ventricular dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular dysfunction</measure>
    <time_frame>During ICU-stay</time_frame>
    <description>Prevalence of right ventricular dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk-factors</measure>
    <time_frame>During ICU-stay</time_frame>
    <description>Clinical variables associated with risk of having cardiac dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac biomarkers</measure>
    <time_frame>During ICU-stay</time_frame>
    <description>Levels of cardiac biomarkers in patients with vs without cardiac dysfunction</description>
  </secondary_outcome>
  <enrollment type="Actual">132</enrollment>
  <condition>Covid19</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>Right Ventricular Dysfunction</condition>
  <condition>Pulmonary Hypertension</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Echocardiography for assessment of cardiac function</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to participating unit, being infected with COVID-19 are eligible for&#xD;
        inclusion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients admitted to the intensive care unit infected with COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jonatan Oras, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <state>Region Stockholm</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Älvsborg County Hospital</name>
      <address>
        <city>Trollhättan</city>
        <state>Västra Götalandsregionen</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital/Mölndal</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>40530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital/Östra</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>40530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Jonatan Oras</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Ventricular Dysfunction, Right</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

